I-Mab
IMAB
View Detailed Chart
4.630USD
0.000
Close 12/26, 16:00（ET）Quotes delayed by 15 min
378.67MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
0.00%
5 Days
0.00%
1 Month
0.00%
6 Months
+80.16%
Year to Date
+444.71%
1 Year
+426.14%
View Detailed Chart
TradingKey Stock Score of I-Mab
Currency: USD Updated: 2025-10-29Key Insights
I-Mab's fundamentals are relatively healthy, Its valuation is considered undervalued, Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at max_target_price.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
I-Mab's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
6
analysts
Strong Buy
Current Rating
8.333
Target Price
+107.30%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
I-Mab Highlights
StrengthsRisks
Novabridge Biosciences is a global biotechnology platform company. The Company combines deep business development expertise with agile translational clinical development to identify, accelerate, and advance breakthrough assets. Its differentiated pipeline includes givastomig, a bispecific antibody (Claudin 18.2 x 4-1BB), and VIS-101, a bifunctional biologic, targeting VEGF-A and ANG2. Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. Givastomig is being developed to treat Claudin 18.2-positive gastric cancer and other gastrointestinal malignancies. VIS-101 targets VEGF-A and ANG-2 to provide more potent and durable treatment benefits for patients with wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). VIS-101 is completing a large, randomized, dose-ranging Phase 2 study for wet AMD.
Undervalued
The company’s latest PE is -9.40, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 23.14M shares, decreasing 46.16% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 63.70K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 3.21.
I-Mab News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
I-Mab Info
Novabridge Biosciences is a global biotechnology platform company. The Company combines deep business development expertise with agile translational clinical development to identify, accelerate, and advance breakthrough assets. Its differentiated pipeline includes givastomig, a bispecific antibody (Claudin 18.2 x 4-1BB), and VIS-101, a bifunctional biologic, targeting VEGF-A and ANG2. Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. Givastomig is being developed to treat Claudin 18.2-positive gastric cancer and other gastrointestinal malignancies. VIS-101 targets VEGF-A and ANG-2 to provide more potent and durable treatment benefits for patients with wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). VIS-101 is completing a large, randomized, dose-ranging Phase 2 study for wet AMD.
Ticker SymbolIMAB
CompanyI-Mab
CEOFu (Xi-Yong)
Websitehttp://www.novabridge.com/#/
FAQs
What is the current price of I-Mab (IMAB)?
The current price of I-Mab (IMAB) is 4.630.
What is the symbol of I-Mab?
The ticker symbol of I-Mab is IMAB.
What is the 52-week high of I-Mab?
The 52-week high of I-Mab is 6.790.
What is the 52-week low of I-Mab?
The 52-week low of I-Mab is 0.595.
What is the market capitalization of I-Mab?
The market capitalization of I-Mab is 378.67M.
What is the net income of I-Mab?
The net income of I-Mab is -22.23M.
Is I-Mab (IMAB) currently rated as Buy, Hold, or Sell?
According to analysts, I-Mab (IMAB) has an overall rating of --, with a price target of 8.333.
What is the Earnings Per Share (EPS TTM) of I-Mab (IMAB)?
The Earnings Per Share (EPS TTM) of I-Mab (IMAB) is -0.492.
Related Instruments
+0.05%
-0.07%
+0.08%
+0.49%
+0.23%
+0.38%
-0.31%
-0.30%
-0.77%
+0.30%
+0.23%
-0.02%
-0.07%
+0.24%
+0.26%
+0.30%
+0.16%
0.00%
+0.58%
-0.02%
